✦ LIBER ✦

A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases

✍ Scribed by Olatoyosi M. Odenike; Ronald M. Sobecks; Linda Janisch; Dezheng Huo; Todd M. Zimmerman; Christopher K. Daugherty; Mark J. Ratain; Richard A. Larson

Publisher: Springer
Year: 2004
Tongue: English
Weight: 202 KB
Volume: 54
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-004-0857-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I combination trial of gemcitabine

Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy

✍ Keith T. Flaherty; James P. Stevenson; Stephen M. Hahn; Maryann Redlinger; Peter 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 178 KB

A phase II trial of gemcitabine plus cap

A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma

✍ Byeong-Bae Park; Joon Oh Park; Hyo Rak Lee; Jeeyun Lee; Dong Wook Choi; Seong-Ho 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 243 KB

Phase I trial of weekly docetaxel and ge

Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies

✍ Tarek Mekhail; Thomas E. Hutson; Paul Elson; G. Thomas Budd; Gordon Srkalovic; T 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 1 views

## Abstract ## BACKGROUND A Phase I study using weekly docetaxel and gemcitabine was conducted to investigate toxicity; to determine the maximum tolerated dose (MTD) of each agent; and, in a preliminary fashion, to determine the antitumor activity of the combination. ## METHODS Docetaxel and gem

A phase I trial of gemcitabine in combin

A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors

✍ William Schelman; Sherry Morgan-Meadows; Howard Bailey; Kyle Holen; James P. Tho 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 325 KB

A phase II trial of gemcitabine in patie

A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma

✍ Charles S. Fuchs; Jeffrey W. Clark; David P. Ryan; Mathew H. Kulke; Haesook Kim; 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 2 views

## Abstract ## BACKGROUND There is no effective systemic therapy for patients with hepatocellular carcinoma. A recent trial reported a moderate antitumor activity for gemcitabine among Asian patients with advanced hepatocellular carcinoma. This led to our examination of the efficacy and tolerabili

A phase I trial of dactinomycin intraven

A phase I trial of dactinomycin intravenous infusion in patients with advanced malignancies

✍ Martin S. Blumenreich; Thomas M. Woodcock; Stephen P. Richman; Mariesa K. Jones; 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 204 KB 👁 3 views

Eighteen patients with advanced malignancies refractory to other forms of treatment were given dactinomycin (Act D) as continuous intravenous infusions. Their median age was 51 years (range, 36-67); their median performance status was 50 (range, 40-90) on the Karnofsky scale. Act D was administered